CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkac1147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Hui Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Rega Institute for Medical Research, Medicinal Chemistry, Herestraat 49, Box 10…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Nucleic Acids. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, European Union’s Horizon 2020 research and innovation program, China Scholarship Council.
Abstract (Originalsprache)
An enzymatic method has been successfully established enabling the generation of partially base-modified RNA (previously named RZA) constructs, in which all G residues were replaced by isomorphic fluorescent thienoguanosine (thG) analogs, as well as fully modified RZA featuring thG, 5-bromocytosine, 7-deazaadenine and 5-chlorouracil. The transcriptional efficiency of emissive fully modified RZA was found to benefit from the use of various T7 RNA polymerase variants. Moreover, dthG could be incorporated into PCR products by Taq DNA polymerase together with the other three base-modified nucleotides. Notably, the obtained RNA products containing thG as well as thG together with 5-bromocytosine could function as effectively as natural sgRNAs in an in vitro CRISPR-Cas9 cleavage assay. N1-Methylpseudouridine was also demonstrated to be a faithful non-canonical substitute of uridine to direct Cas9 nuclease cleavage when incorporated in sgRNA. The Cas9 inactivation by 7-deazapurines indicated the importance of the 7-nitrogen atom of purines in both sgRNA and PAM site for achieving efficient Cas9 cleavage. Additional aspects of this study are discussed in relation to the significance of sgRNA–protein and PAM–-protein interactions that were not highlighted by the Cas9–sgRNA–DNA complex crystal structure. These findings could expand the impact and therapeutic value of CRISPR-Cas9 and other RNA-based technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Rega Institute for Medical Research, Medicinal Chemistry, Herestraat 49, Box 1041, 3000 Leuven, Belgium.
- Queensland University of Technology, Centre for Agriculture and the Bioeconomy, Molecular Engineering Group, George Street 2, 4000 Brisbane, Queensland, Australia.
- KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49, Box 1043, 3000 Leuven, Belgium.
- University of Padova, Department of Pharmaceutical and Pharmacological Sciences, Via Marzolo 5, 35131 Padova, Italy.
ORCID-Profile: Piet Herdewijn
Förderung
- Fonds Wetenschappelijk Onderzoek
- European Union’s Horizon 2020 research and innovation program
- China Scholarship Council
Zitieren
APA
Yang, H., Eremeeva, E., Abramov, M., Jacquemyn, M., Groaz, E., Daelemans, D., & Herdewijn, P. (2023). CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids. Nucleic Acids Research. https://doi.org/10.1093/nar/gkac1147
Vancouver
Yang H, Eremeeva E, Abramov M, Jacquemyn M, Groaz E, Daelemans D, et al. CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids. Nucleic Acids Research. 2023. doi:10.1093/nar/gkac1147
BibTeX
@article{Yang2023,
author = {Yang, Hui and Eremeeva, Elena and Abramov, Mikhail and Jacquemyn, Maarten and Groaz, Elisabetta and Daelemans, Dirk and Herdewijn, Piet},
title = {CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkac1147}
}
EUVIMED